Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the combination of sacituzumab tirumotecan and pembrolizumab compared to pembrolizumab alone in treating people with metastatic non-small cell lung cancer NSCLC who have high levels of PD-L1 expression at least 50%. The study aims to see whether adding sacituzumab tirumotecan improves overall survival compared to pembrolizumab alone. This is a phase 3, randomized, open-label trial sponsored by Merck Sharp & Dohme LLC. Participants are randomly assigned to receive either sacituzumab tirumotecan plus pembrolizumab or pembrolizumab alone. Sacituzumab tirumotecan is given by intravenous infusion on Days 1, 15, and 29 of each 6-week cycle, while pembrolizumab is administered by intravenous infusion on Day 1 of each 6-week cycle for up to 18 cycles. Supportive medications such as diphenhydramine, an H2 antagonist, acetaminophen, and dexamethasone are given around the first four infusions of sacituzumab tirumotecan to help manage infusion reactions. During the study, participants undergo assessments including overall survival, progression-free survival, response rates, and quality of life measured by validated questionnaires. Safety is monitored throughout the treatment period and beyond. The study tracks symptoms like cough, chest pain, and breathing difficulties, along with adverse events and treatment discontinuations. The total follow-up for outcomes may extend up to approximately 77 months, allowing for long-term monitoring of treatment effects and safety.